← Back to Search

Beta-3 Adrenergic Receptor Agonist

Mirabegron for Type 2 Diabetes (GB9 Trial)

N/A
Waitlist Available
Led By Denis Blondin
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 150 minutes before and mean of time 180, 240 and 300 minutes after drug administration (steady state).
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combination of two drugs for young to middle-aged people with Type 2 Diabetes. One drug helps control blood sugar, and the other prevents heart-related side effects.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state).
This trial's timeline: 3 weeks for screening, Varies for treatment, and 150 minutes before and mean of time 210 and 270 minutes after drug administration (steady state). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
BAT glucose uptake
Change in activation of Brown Adipose Tissue (BAT) (oxidative metabolism and blood flow)
Secondary study objectives
BAT lipolysis
Changes in pancreatic and gut hormones
Hepatic Glucose production
+3 more

Side effects data

From 2019 Phase 4 trial • 28 Patients • NCT02086188
7%
headache
7%
asthma
7%
diarrhea
7%
gastritis
7%
urinary tract infection
7%
fatigue
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Mirabegron

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Study BExperimental Treatment2 Interventions
Metabolic PET study with mirabegron and bisoprolol
Group II: Study AActive Control1 Intervention
Metabolic PET study with mirabegron
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mirabegron
2008
Completed Phase 4
~18640
Bisoprolol Fumarate
2021
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

Université de SherbrookeLead Sponsor
304 Previous Clinical Trials
76,720 Total Patients Enrolled
Laval UniversityOTHER
430 Previous Clinical Trials
178,386 Total Patients Enrolled
Denis BlondinPrincipal InvestigatorUniversité de Sherbrooke
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top